| 000 | 05722cam a2200805Ia 4500 | ||
|---|---|---|---|
| 001 | sulb-eb0032974 | ||
| 003 | BD-SySUS | ||
| 005 | 20170713221350.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 131206s2014 gw ob 001 0 eng d | ||
| 040 |
_aIDEBK _beng _epn _cIDEBK _dEBLCP _dDG1 _dN$T _dYDXCP _dOCLCF _dOCLCQ _dDEBSZ _dCOO _dDEBBG _dOCLCQ _dCDX _dBD-SySUS |
||
| 019 |
_a870511683 _a961643563 _a962637366 |
||
| 020 |
_a9783527677283 _q(electronic bk.) |
||
| 020 |
_a3527677283 _q(electronic bk.) |
||
| 020 |
_a9783527677252 _q(electronic bk.) |
||
| 020 |
_a3527677259 _q(electronic bk.) |
||
| 020 |
_a1306168902 _q(electronic bk.) |
||
| 020 |
_a9781306168908 _q(electronic bk.) |
||
| 020 | _a9783527333943 | ||
| 020 | _a3527333940 | ||
| 020 |
_a9783527677269 _q(Mobi) |
||
| 020 |
_a3527677267 _q(Mobi) |
||
| 020 |
_a9783527677276 _q(ePub) |
||
| 020 |
_a3527677275 _q(ePub) |
||
| 029 | 1 |
_aDEBBG _bBV043396386 |
|
| 029 | 1 |
_aDEBSZ _b43157054X |
|
| 029 | 1 |
_aNZ1 _b15495746 |
|
| 029 | 1 |
_aNZ1 _b15905579 |
|
| 035 |
_a(OCoLC)864744144 _z(OCoLC)870511683 _z(OCoLC)961643563 _z(OCoLC)962637366 |
||
| 037 |
_a548141 _bMIL |
||
| 050 | 4 | _aRS403 | |
| 050 | 4 |
_aRM111 _b.L384 2013 |
|
| 060 | 4 | _aQV 744 | |
| 072 | 7 |
_aMED _x071000 _2bisacsh |
|
| 082 | 0 | 4 |
_a615.1/9 _223 |
| 049 | _aMAIN | ||
| 245 | 0 | 0 |
_aMedicinal chemistry approaches to personalized medicine / _cedited by Karen Lackey and Bruce D. Roth. |
| 260 |
_aWeinheim : _bWiley-VCH, _c2014. |
||
| 300 | _a1 online resource. | ||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 490 | 1 |
_aMedicinal chemistry ; _vVolume 59 |
|
| 504 | _aIncludes bibliographical references and index. | ||
| 588 | 0 | _aPrint version record. | |
| 505 | 0 | _aMethods and Principles in Medicinal Chemistry; Title Page; Copyright; List of Contributors; Foreword; Preface; A Personal Foreword; Acronyms; Chapter 1: Medicinal Chemistry Approaches to Creating Targeted Medicines; 1.1 Introduction; 1.2 Role of Medicinal Chemistry in Drug Discovery; 1.3 Evolution of Molecular Design for Subsets of Patients; 1.4 Combinations for Effective Therapies; 1.5 Biomarkers in Targeting Patients; 1.6 Emerging Field of Epigenetics; 1.7 Systems Chemical Biology; 1.8 Theranostics and Designing Drug Delivery Systems | |
| 505 | 8 | _a1.9 Rapid Progress in Further Personalizing Medicine ExpectedReferences; Chapter 2: Discovery of Predictive Biomarkers for Anticancer Drugs; 2.1 Introduction; 2.2 "Oncogene Addiction" as a Paradigm for Clinical Implementation of Predictive Biomarkers; 2.3 Cancer Cell Lines as a Model System for Discovery of Predictive Biomarkers; 2.4 Modeling Drug Resistance to Discover Predictive Biomarkers; 2.5 Discovery of Predictive Biomarkers in the Context of Treatment Combinations; 2.6 Discovery of Predictive Biomarkers for Antiangiogenic Agents; 2.7 Gene Expression Signatures as Predictive Biomarkers | |
| 505 | 8 | _a2.8 Current Challenges in Discovering Predictive Biomarkers2.9 Future Perspective; References; Chapter 3: Crizotinib; 3.1 Introduction; 3.2 Discovery of Crizotinib ( PF -02341066) [40]; 3.3 Kinase Selectivity of Crizotinib; 3.4 Pharmacology of Crizotinib [45,46]; 3.5 Human Clinical Efficacies of Crizotinib; 3.6 Summary; References; Chapter 4: Discovery and Development of Vemurafenib: First-in-Class Inhibitor of Mutant BRAF for the Treatment of Cancer; 4.1 Background; 4.2 Discovery and Development of Vemurafenib (PLX4032); 4.3 Pharmacology; 4.4 Clinical Efficacy and Safety | |
| 505 | 8 | _a4.5 Companion Diagnostic (cobas 4800) Development4.6 Synthesis; 4.7 Summary; References; Chapter 5: Targeting Basal-Cell Carcinoma: Discovery and Development of Vismodegib ( GDC -0449), a First-in-Class Inhibitor of the Hedgehog Pathway; 5.1 Introduction; 5.2 Hedgehog and Basal-Cell Carcinoma; 5.3 Cyclopamine as an SMO Antagonist; 5.4 Small-Molecule Inhibitors of SMO; 5.5 Preclinical Characterization of Vismodegib; 5.6 Vismodegib Clinical Experience in Phase I; References; Chapter 6: G-Quadruplexes as Therapeutic Targets in Cancer; 6.1 Introduction; 6.2 Quadruplex Fundamentals | |
| 505 | 8 | _a6.3 Genomic Quadruplexes6.4 Quadruplexes in Human Telomeres; 6.5 Quadruplexes as Anticancer Targets -- Evidence from In Vivo Studies; 6.6 Native Quadruplex Structures; 6.7 Quadruplex-Small-Molecule Structures; 6.8 Developing Superior Quadruplex-Binding Ligands; 6.9 Conclusions; References; Chapter 7: Identifying Actionable Targets in Cancer Patients; 7.1 Introduction and Background; 7.2 Overview of Genomic Sequencing and Its Impact on the Identification of Actionable Mutations; 7.3 Actionable Targets by Clinical Molecular Profiling: the OICR / PMH Experience | |
| 650 | 0 | _aPharmaceutical chemistry. | |
| 650 | 7 |
_aMEDICAL _xPharmacology. _2bisacsh |
|
| 650 | 7 |
_aPharmaceutical chemistry. _2fast _0(OCoLC)fst01060115 |
|
| 655 | 4 | _aElectronic books. | |
| 655 | 0 | _aElectronic books. | |
| 700 | 1 | _aLackey, Karen. | |
| 700 | 1 | _aRoth, Bruce D. | |
| 776 | 0 | 8 |
_iPrint version: _tMedicinal chemistry approaches to personalized medicine. _dWeinheim : Wiley-VCH, 2014 _z9783527677252 |
| 830 | 0 |
_aMedicinal chemistry ; _vVolume 59. |
|
| 856 | 4 | 0 |
_uhttp://onlinelibrary.wiley.com/book/10.1002/9783527677252 _zWiley Online Library [Free Download only for SUST IP] |
| 938 |
_aEBL - Ebook Library _bEBLB _nEBL1569033 |
||
| 938 |
_aEBSCOhost _bEBSC _n668292 |
||
| 938 |
_aIngram Digital eBook Collection _bIDEB _ncis26870791 |
||
| 938 |
_aYBP Library Services _bYANK _n10706499 |
||
| 938 |
_aYBP Library Services _bYANK _n11387981 |
||
| 938 |
_aYBP Library Services _bYANK _n12679603 |
||
| 938 |
_aCoutts Information Services _bCOUT _n26870791 |
||
| 994 |
_a92 _bDG1 |
||
| 999 |
_c64626 _d64626 |
||